{'fraction_non_alphanumeric': 0.03391472868217054, 'fraction_numerical': 0.023255813953488372, 'mean_word_length': 6.124137931034483, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ticlopidine‐induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy

Severe aplastic anemia is a well‐recognized complication of ticlopidine therapy that carries a high mortality. Therapy with colony‐stimulating factors or corticosteroids has been largely ineffective in this disorder. We report a case of ticlopidine‐induced aplastic anemia that was successfully treated with cyclosporine and high‐dose dexamethasone. The patient rapidly responded to immunosuppressive therapy and had a normal hemogram after cessation of immunosuppression. On long‐term follow‐up, the patient developed a progressive macrocytic anemia. Repeat bone marrow evaluation demonstrated myelodysplasia with erythroid hypoplasia. An associated chromosomal abnormality consisting of a t(3;16) (q21; p13.3) translocation was detected. This is the first report of a chromosomal abnormality associated with ticlopidine induced marrow aplastic anemia. Am. J. Hematol. 63:141–144, 2000. © 2000 Wiley‐Liss, Inc.